Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2015

View Archived Issues

Recent FDA orphan drug designations given to cancer products

ISA-101 assessed in phase II combination trial with checkpoint inhibitor nivolumab

Imetelstat shows promise for refractory anemia

Novel Ras inhibitors from ADT Pharmaceuticals suppress tumor growth in vivo

Partikula's KULA-101 inhibits multiple immune checkpoint proteins in study

CytRx selects DK-049 for clinical development next year

EMA accepts MAA for Gedeon Richter's biosimilar pegfilgrastim

R-Pharm begins global phase III trial program for olokizumab

Sucampo acquires R-Tech Ueno

Treeway and Cedars-Sinai collaborate to advance AAV5-GDNF gene therapy for ALS

Merck KGaA terminates development of evofosfamide

Eli Lilly presents clinical results for emibetuzumab

Gamida Cell discloses results from phase I/II trial of NiCord

Technique devised for imaging platelets in thrombosis models

Novo Nordisk files for regulatory approval of faster-acting insulin aspart in the U.S. and E.U.

Experimental cardiac arrest and resuscitation uses aged animals

Ignyta initiates pediatric study of entrectinib

BMS completes acquisition of Cardioxyl Pharmaceuticals

Tetra Discovery Partners initiates phase I trials of BPN-14770 for Alzheimer's disease

Pluristem and United Therapeutics end licensing agreement for PLX-PAD

Purdue Canada acquires Merck & Co.'s ophthalmology franchise under Mundipharma deal

Mexico approves Dengvaxia, world's first dengue vaccine

New alliances target neurodegenerative diseases and KCNQ2 epileptic encephalopathy

Shanghai Fochon Pharmaceutical patents CDK4/6 inhibitors

Kyung Hee University discloses T-type calcium channel blockers

Tangrun Pharmaceuticals develops HCV NS5A inhibitors

Roche acquires Kapa Biosystems to potentiate NGS product offerings

Bayer Schering Pharma presents MNK1 inhibitors

GlaxoSmithKline reports CXCR2 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...